Information Provided By:
Fly News Breaks for September 7, 2017
TXMD
Sep 7, 2017 | 12:38 EDT
TherapeuticsMD management last night participated in a conference call with Dr. Kaunitz, a co-author of the recently published National Institutes of Health paper on vaginal estrogen and safety observations from the Women's Health Initiative Observational Study, Jefferies analyst Matthew Andrews tells investors in a research note. Kaunitz believes the data reinforce the long-term safety of vaginal estrogen, and does not believe there is a safety signal for elevated endometrial cancers, the analyst adds. Andrews admits that there are limitations with the study. He has a Buy rating on TherapeuticsMD with a $15 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD